10 results on '"Sorella Ilveskero"'
Search Results
2. A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
- Author
-
Marja Sankelo, Conny Karlsson, Mona Hoysaeter Fenstad, Maija Mikkola, Damian L. Szatkowski, Johanna Abelsson, Kristina Carlson, Per Axelsson, Valdas Peceliunas, Hareth Nahi, Anu Partanen, Mervi Putkonen, Anu Sikiö, Pekka Anttila, Fredrik Schjesvold, Marjaana Säily, Monika Klimkowska, Raija Silvennoinen, Anu Marttila, Erik Ahlstrand, Sorella Ilveskero, Lucia Ahlberg, Birgitta Lauri, Reda Matuzeviciene, Markus Hansson, Einar Haukaas, and Anders Waage
- Subjects
medicine.medical_specialty ,Cyclophosphamide ,Immunology ,Phases of clinical research ,030204 cardiovascular system & hematology ,Biochemistry ,Ixazomib ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Autologous stem-cell transplantation ,Internal medicine ,medicine ,Multiple myeloma ,Lenalidomide ,business.industry ,Standard treatment ,Cell Biology ,Hematology ,medicine.disease ,Minimal residual disease ,3. Good health ,chemistry ,030220 oncology & carcinogenesis ,business ,medicine.drug - Abstract
Introduction Autologous stem cell transplantation (ASCT) combined with novel agents is considered as the standard treatment for eligible patients < 70(-75) years of age with multiple myeloma (MM). The number of induction cycles is usually 4-6 followed by ASCT, consolidation and maintenance. The role of consolidation is still under debate especially if complete response has been achieved and maintenance will follow. To improve the quality of life and avoid the frequent visits at hospital an all-oral treatment would be a preferred choice. Despite novel drugs, the outcome of high-risk (HR) patients is poor. We designed a phase 2 Nordic Myeloma Study Group (NMSG) trial (NCT03376672) to explore the response of ixazomib, lenalidomide and dexamethasone (IRd) induction, followed by single ASCT, IRd consolidation and risk-based maintenance either with IR or R. Here we present the response rates and safety after IRd x 4 induction in all patients and in 87% of patients before consolidation. Patients and methods This study included 120 patients in 22 NMSG sites. Patients received 4 IRd cycles as induction, ixazomib 4 mg on days 1, 8, 15, lenalidomide 25 mg on days 1-21, dexamethasone 40 mg weekly in 28-day cycles. Mobilization and ASCT were performed according to standard practice. Three months post-ASCT all patients will receive 2 IRd as consolidation followed by maintenance. Thereafter patients will be stratified to HR if any of the following FISH aberrations were found at inclusion: del17p at least 60%, t(4;14), t(14;16), t(14;20) or +1q and they receive ixazomib 4 mg on days 1, 8, 15 and lenalidomide 10 mg on days 1-21. Non-HR patients receive lenalidomide 10 mg on days 1-21. Maintenance will continue until progression (PD). Lenalidomide dose will increase to 15 mg after 3 cycles. The primary endpoint of the study is minimal residual disease (MRD) by 8-color Euroflow < 0.01%. The secondary endpoints include flow-MRD negativity by 10-5, overall response, safety and progression-free survival. Serological responses were assessed before cycles and if sCR or CR is achieved flow-MRD sampling will be performed and repeated every 6 months. Samples were taken concomitantly for later comparison with BM- molecular-MRD, blood cell-free DNA, blood heavy-light chain assay and blood mass spectrometry. Results Within 21 months 120 patients were included, 46 % of them belong to the HR group. Mobilization is by July 2020 performed for 101 (84%) patients with cyclophosphamide (Cy) + G-CSF in 74% and G-CSF alone in 26%. Plerixafor was needed in 32 (32%) patients. The median number of harvesting days was 2 (0-4) and the median number of collected CD34+ cells was 6.4 (0-19.2) x 106/kg. Four patients (4%) failed to mobilize during 1st attempt. Eighty-six (72%) patients have so far received ASCT with the median number of 3.4 x 106/kg CD34+ cells in graft. Overall response rate is 93%. The responses after IRD x 4 induction and before consolidation are presented in Table 1. Before consolidation 10 patients (8%) are out of study due to PD and 4 (3%) have been withdrawn due to toxicity. Toxicity events included hypersensitivity with hepatorenal failure, grade 3 cytopenia with liver toxicity and one unexplained encephalitis. One patient was withdrawn due to Cy toxicity. Eight additional patients are withdrawn from study, 7 by physician´s decision and 1 by patient´s decision. All these 7 patients had high tumor burden based on paraprotein level either in serum (53 - 102 g/L) or in 24h urine (7.8 - 23.2 g/24h) and achieved only stable disease (SD) during induction. Fifty-eight grade 3-4 SAE reports from 39 (33%) patients have been received and 57% of these were infections. Three patients had grade 3 liver problems and 2 patients grade 3 peripheral neuropathy. Seventeen (14%) patients have reported skin reactions, only 4 of them grade 3 events. Conclusion We present here data on response and safety after observation of all patients until post-induction phase and of 87 % of the patients until start of the consolidation phase. The ORR is 93% when all patients have received induction treatment. Nine patients achieved only SD and seven of them with high tumor burden were withdrawn before mobilization. At least VGPR after ASCT was achieved in 37%. Toxicity caused the withdrawal of 4 (3%) patients and 39 (33%) patients have reported grade 3-4 non-hematological SAEs. In all, 98/120 (82%) patients continue in the study including 80% of the HR patients. Disclosures Silvennoinen: BMS: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Cancer patients Finland: Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding. Waage:Janssen: Consultancy, Honoraria, Speakers Bureau; Takeda: Consultancy; Shire: Honoraria. Schjesvold:Celgene, Amgen, Janssen, Oncopeptides: Research Funding; Amgen, Celgene, Janssen, MSD, Novartis, Oncopeptides, Sanofi, SkyliteDX, Takeda: Honoraria; Amgen, Celgene, Janssen, MSD, Novartis, Oncopeptides, Sanofi, Takeda: Consultancy. Anttila:Sanofi: Research Funding; Amgen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; BMS: Research Funding; Janssen: Honoraria, Other: Advisory Board; Takeda: Honoraria, Research Funding. Säily:Amgen: Honoraria; Abbvie: Honoraria; Celgene: Honoraria; Roche: Honoraria; Sanofi: Honoraria; Pfizer: Honoraria; Takeda: Honoraria; Janssen Cilag: Honoraria; Boehringer Ingelheim: Honoraria. Sankelo:Celgene, Amgen, Sanofi: Other: Congress travel support. Partanen:Abbvie: Honoraria, Other: Scientific Advisory Board Meeting; Behring: Honoraria; Takeda: Other: Scientific Advisory Board Meeting.
- Published
- 2020
3. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma:a phase 2 study of the Finnish Myeloma Group
- Author
-
Anri Tienhaara, Tuomas Selander, Tuija Lundán, Anu Partanen, Venla Terävä, Pekka Anttila, Marja Sankelo, Marjaana Säily, Jouni Heiskanen, Piotr Bazia, Sorella Ilveskero, Anu Räsänen, Merja Suominen, Kristiina Kananen, Sini Luoma, Kirsi Launonen, Pentti Mäntymaa, V. Huotari, Esa Jantunen, Juha Lievonen, Tarja-Terttu Pelliniemi, Timo Siitonen, Hanna Ollikainen, Raija Silvennoinen, Sakari Kakko, Mervi Putkonen, and Anu Sikiö
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Cyclophosphamide ,Maintenance ,Dexamethasone ,Disease-Free Survival ,Maintenance Chemotherapy ,Bortezomib ,Autologous stem-cell transplantation ,Multiple myeloma ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,Flow cytometry ,Autografts ,Lenalidomide ,Finland ,Aged ,business.industry ,Standard treatment ,Minimal residual disease ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Survival Rate ,PCR ,Female ,Original Article ,business ,medicine.drug ,Stem Cell Transplantation - Abstract
Autologous stem cell transplantation (ASCT) combined with novel agents is the standard treatment for transplant-eligible, newly diagnosed myeloma (NDMM) patients. Lenalidomide is approved for maintenance after ASCT until progression, although the optimal duration of maintenance is unknown. In this trial, 80 patients with NDMM received three cycles of lenalidomide, bortezomib, and dexamethasone followed by ASCT and lenalidomide maintenance until progression or toxicity. The primary endpoint was the proportion of flow-negative patients. Molecular response was assessed if patients were flow-negative or in stringent complete response (sCR). By intention to treat, the overall response rate was 89%. Neither median progression-free survival nor overall survival (OS) has been reached. The OS at 3 years was 83%. Flow-negativity was reached in 53% and PCR-negativity in 28% of the patients. With a median follow-up of 27 months, 29 (36%) patients are still on lenalidomide and 66% of them have sustained flow-negativity. Lenalidomide maintenance phase was reached in 8/16 high-risk patients but seven of them have progressed after a median of only 6 months. In low- or standard-risk patients, the outcome was promising, but high-risk patients need more effective treatment approach. Flow-negativity with the conventional flow was an independent predictor for longer PFS. Electronic supplementary material The online version of this article (10.1007/s00277-019-03815-7) contains supplementary material, which is available to authorized users.
- Published
- 2019
4. A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines
- Author
-
Juha Lievonen, Sorella Ilveskero, Sini Luoma, Marja Sankelo, Pekka Anttila, Muntasir Mamun Majumder, Tarja-Terttu Pelliniemi, Esa Jantunen, Anu Sikiö, Ville Varmavuo, Caroline A. Heckman, Anu Räsänen, Anu Partanen, Dimitrios Tsallos, Maija Leppä, Marjaana Säily, Samuli Eldfors, Marita Nurmi, Raija Silvennoinen, Hareth Nahi, and Perttu Koskenvesa
- Subjects
Oncology ,medicine.medical_specialty ,Immunology ,Phases of clinical research ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Clinical endpoint ,Progression-free survival ,Elotuzumab ,Multiple myeloma ,030304 developmental biology ,0303 health sciences ,business.industry ,Bortezomib ,SLAMF7 ,Cell Biology ,Hematology ,medicine.disease ,Carfilzomib ,3. Good health ,chemistry ,030220 oncology & carcinogenesis ,business ,medicine.drug - Abstract
Introduction: The median progression free survival (PFS) and overall survival (OS) of multiple myeloma (MM) patients have been prolonged due to novel agents combined with ASCT but the median OS in MM is still 7-8 years. Thus, the feasibility of new combinations and dosing of available agents must be investigated. The first proteasome inhibitor (PI), bortezomib (B), combined with elotuzumab and dexamethasone (d) showed superiority to Bd with PFS of 9.7 vs. 6.9 months, respectively, without excessive toxicity (Jakubowiak et al. Blood 2016;127:2833-40). In our study we investigate the safety, feasibility and initial efficacy of a second generation PI carfilzomib (K), SLAMF7 antibody elotuzumab (E) and dexamethasone (D) combination (KED) in relapsed or refractory MM (RRMM) patients. Patients and methods: Forty RRMM patients after 1-3 prior lines will be included in this phase 2 study after written informed consent. The primary endpoint is overall response rate (ORR). In patients achieving at least very good partial remission (VGPR) the quality of response will be assessed with high-sensitivity multicolour flow cytometry (MFC) according to the 8-colour EuroFlow protocol. Carfilzomib is given once weekly 20 mg/m2 on D1C1 and thereafter 70 mg/m2 in 28 day cycles on days 1, 8 and 15 in cycles 1-8 and on days 1 and 15 thereafter combined with weekly elotuzumab 10 mg/kg on days 1, 8 and 15 in cycles 1-2, thereafter on days 1 and 15; dexamethasone 40 mg on days 1, 8, 15 and 22 on cycles 1-8, thereafter on days 1 and 15. Treatment will continue until progression or excessive toxicity. Carfilzomib dose was 20/56 mg/m2 for the first two cycles for the first five patients to evaluate the safety. Additionally, patient samples collected prior to treatment will be comprehensively profiled by whole exome and RNA sequencing and evaluated for ex vivo response to the agents. Together, the study addresses clinical response, ex vivo-in vivo translation, identifies molecular biomarkers for the KED combination and facilitates precision guided clinical trials for RRMM. Results: By the end of July 2018, 11 patients have been enrolled. Median number of prior lines was 2 (1-3). Seven IgG-κ, two IgA-κ and one kappa and lambda light-chain patient are included. After a median of 6 (2-12) cycles ORR is 91% with 3 patients in VGPR (median MFC-MRD of 0,002%), 7 patients in PR, one in MR. Initial molecular characterization highlighted diverse subclonal backgrounds among the treated patients (Figure 1), but interestingly, the best responding VGPR patients displayed mutations to RAS genes in the dominant clones (NRAS 828, 2662; KRAS 733). At least PR was achieved after a median of 1 (1-4) cycle. Three patients have progressed and one patient withdrawn due to suspected thrombotic microangiopathy with manifestation of convulsions and pulmonary embolism. We noticed only one grade 2 infusion reaction after premedication. One patient developed autoimmune hemolytic anemia (AIHA), without red cell antibodies, suspected to be related to elotuzumab. She recovered with steroids and elotuzumab discontinuation and continued Kd without reappearance of AIHA. Another patient had grade 3 liver transaminase elevation but was able to continue treatment with dose reduction of carfilzomib and dexamethasone. Conclusion: To the best of our knowledge this is the first study evaluating the carfilzomib, elotuzumab and dexamethasone combination in RRMM with comprehensive molecular annotations. Among this small group of patients we noticed two unexpected severe adverse events; atypical AIHA and suspected thrombotic microangiopathy. AIHA should be excluded if unexpected anemia will appear during elotuzumab treatment. Preliminary results of this KED combination showed efficacy in patients with clonal RAS mutations and ORR of 91% after the median of two prior treatment lines using weekly carfilzomib dose of 70 mg/m2. Figure 1: Subclonal diversity in patient derived plasma cells. Clonal and subclonal fractions were evaluated by assessing peaks of variant allele frequencies of somatic mutations present in the myeloma plasma cells using kernel density estimation. For each plot, the fraction of cells carrying the mutation is represented on the x axis (1 = 100% of cells), and the probability density on the y axis. The mutated cell fraction (x axis) was calculated by adjusting mutant allele burden by copy number of the mutated loci. Disclosures Silvennoinen: Takeda: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Amgen: Honoraria, Research Funding. Tsallos:Novartis: Research Funding. Anttila:Amgen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Räsänen:Amgen: Honoraria. Luoma:Amgen: Honoraria. Jantunen:Amgen: Honoraria; Genzyme/Sanofi: Honoraria; Takeda: Honoraria. Heckman:Celgene: Research Funding; Orion Pharma: Research Funding; Novartis: Research Funding.
- Published
- 2018
5. Monitoring high-dose heparinization during cardiopulmonary bypass – A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays
- Author
-
Sorella Ilveskero, Peter Raivio, Jari Petäjä, Anne Kuitunen, and Riitta Lassila
- Subjects
Adult ,Male ,medicine.drug_mechanism_of_action ,medicine.drug_class ,Factor Xa Inhibitor ,Blood Loss, Surgical ,Coronary Artery Disease ,Pharmacology ,Antithrombins ,Thromboplastin ,Fibrin Fibrinogen Degradation Products ,Prothrombinase ,Monitoring, Intraoperative ,medicine ,Humans ,Prospective Studies ,Coronary Artery Bypass ,Blood Coagulation ,Aged ,Blood coagulation test ,Aged, 80 and over ,Fibrin ,Cardiopulmonary Bypass ,Heparin ,business.industry ,Antithrombin ,Anticoagulant ,Anticoagulants ,Hematology ,Middle Aged ,Peptide Fragments ,Chromogenic Compounds ,Clotting time ,Coagulation ,Biochemistry ,Factor Xa ,Female ,Prothrombin ,Blood Coagulation Tests ,Drug Monitoring ,Erythrocyte Transfusion ,business ,Factor Xa Inhibitors ,Protein C ,circulatory and respiratory physiology ,medicine.drug - Abstract
SummaryHeparinization requires monitoring, but optimal methods for measuring the anticoagulant effects of heparin remain to be determined. We compared prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity (anti-Xa) assays in monitoring high-dose heparinization during cardiopulmonary by-pass (CPB). Heparin effects were serially measured with PiCT and two anti-Xa assays in 100 patients. Antithrombin and protein C activities were measured preoperatively, and antithrombin activity was measured during CPB. Activation of coagulation was assessed with measurements of prothrombin fragment F1+2, soluble fibrin complexes, and D-dimer before, during, and after CPB. During CPB mean ranges of PiCT and of anti-Xa heparin levels measured with (anti-Xa A) and without (anti-Xa B) dextran sulfate and antithrombin supplementation were 5.0–5.2, 4.7–5.0, and 4.5–4.9 IU/ml, respectively. There was poor agreement between PiCT and anti-Xa and between the two anti-Xa assays (r=0.32–0.65 and broad limits of agreement). Patients with low preoperative antithrombin or protein C levels had lower PiCT (p=0.028 and p=0.01) and anti-Xa A (both p
- Published
- 2008
6. D-dimer Predicts Outcome after Aneurysmal Subarachnoid Hemorrhage: No Effect of Thromboprophylaxis on Coagulation Activity
- Author
-
Jari Siironen, Riitta Lassila, Sorella Ilveskero, and Seppo Juvela
- Subjects
Male ,Serine Proteinase Inhibitors ,Time Factors ,Subarachnoid hemorrhage ,medicine.medical_treatment ,law.invention ,Fibrin Fibrinogen Degradation Products ,Fibrinolytic Agents ,Randomized controlled trial ,Predictive Value of Tests ,law ,Plasminogen Activator Inhibitor 1 ,D-dimer ,Fibrinolysis ,Humans ,Medicine ,cardiovascular diseases ,Enoxaparin ,Blood Coagulation ,business.industry ,Vascular disease ,Subarachnoid Hemorrhage ,medicine.disease ,Thrombosis ,Clinical trial ,Treatment Outcome ,Coagulation ,Anesthesia ,Female ,Surgery ,Blood Coagulation Tests ,Neurology (clinical) ,business - Abstract
Objective Approximately one-third of all patients with acute nontraumatic subarachnoid hemorrhage (SAH) experience complications owing to delayed ischemic deficit. We reported recently that enoxaparin 40 mg once daily for 10 days seems safe and demonstrates thromboprophylactic efficacy, but it failed to improve outcome in a randomized SAH trial. In the present study, we assessed hemostatic variables associated with clinical status and outcome of SAH. We also monitored the effect of enoxaparin on activation of coagulation and fibrinolysis after closure of the ruptured aneurysm. Methods Blood samples to measure activation of coagulation and fibrinolysis were collected from 42 patients participating in the enoxaparin trial for acute aneurysmal SAH at four time points: 1) at hospital admission; 2) 12 to 24 hours after aneurysm surgery but before initiation of enoxaparin therapy; 3) 3 hours after the first dose; and 4) at the conclusion of treatment. Results At admission, several variables of coagulation and fibrinolysis were elevated and correlated well with clinical status. Specifically, D-dimer levels at all four time points correlated with patients' long-term outcomes. A single dose of enoxaparin suppressed early coagulation activity, but thrombin generation was not inhibited during thromboprophylaxis. However, PAI-1 activity was suppressed. Conclusion D-dimer offers a useful laboratory tool for assessing early and late clinical severity of SAH. A thromboprophylactic dose of enoxaparin inhibited PAI-1 activity but failed to down-regulate coagulation activity and D-dimer. These findings are compatible with the lack of efficacy of enoxaparin in reducing ischemic deficit after SAH.
- Published
- 2005
7. Procoagulant Activity on Platelets Adhered to Collagen or Plasma Clot
- Author
-
Pia Siljander, Riitta Lassila, and Sorella Ilveskero
- Subjects
Blood Platelets ,Platelet Aggregation ,Fibrin ,Tissue factor ,Platelet Adhesiveness ,Thrombin ,medicine ,Humans ,Platelet ,Platelet Activating Factor ,Thrombus ,Blood Coagulation ,Hemostasis ,biology ,Platelet Count ,Chemistry ,Thrombosis ,Adhesion ,medicine.disease ,Blood Coagulation Factors ,Coagulation ,Biochemistry ,Biophysics ,biology.protein ,Collagen ,Cardiology and Cardiovascular Medicine ,medicine.drug - Abstract
Abstract —In a new 2-stage assay of platelet procoagulant activity (PCA), we first subjected gel-filtered platelets to adhesion on collagen (as a model of primary hemostasis) or plasma clots (as a model of preformed thrombus) for 30 minutes, and then the adherent platelets were supplemented with pooled, reptilase-treated, diluted plasma. Defibrinated plasma provided coagulation factors for assembly on platelet membranes without uncontrolled binding of thrombin to fibrin(ogen). Platelet adhesion to both surfaces showed modest individual variation, which increased at platelet densities that allowed aggregation. However, adhesion-induced PCA varied individually and surface-independently >3-fold, suggesting a uniform platelet procoagulant mechanism. Permanently adhered platelets showed markedly enhanced PCA when compared with the platelet pool in suspension, even after strong activation. The rate of thrombin generation induced by clot-adherent platelets was markedly faster than on collagen-adherent platelets during the initial phase of coagulation, whereas collagen-induced PCA proceeded slowly, strongly promoted by tissue thromboplastin. Therefore at 10 minutes, after adjustment for adhered platelets, collagen supported soluble thrombin formation as much as 5 times that of the thrombin-retaining clots. Activation of platelets by their firm adhesion was accompanied by formation of microparticles, representing about one third of the total soluble PCA. Collagen-adhered platelets provide soluble thrombin and microparticles, whereas the preformed clot serves to localize and accelerate hemostasis at the injury site, with the contribution of retained thrombin and microparticles.
- Published
- 2001
8. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists
- Author
-
Riitta Lassila and Sorella Ilveskero
- Subjects
Platelet Aggregation ,Abciximab ,Eptifibatide ,Platelet Glycoprotein GPIIb-IIIa Complex ,Platelet Membrane Glycoproteins ,Pharmacology ,Immunoglobulin Fab Fragments ,Platelet Adhesiveness ,Platelet adhesiveness ,medicine ,Humans ,Platelet ,Platelet-poor plasma ,Models, Statistical ,Dose-Response Relationship, Drug ,Chemistry ,Coagulants ,Antibodies, Monoclonal ,Convulxin ,Hematology ,Tirofiban ,Adenosine Diphosphate ,C-Reactive Protein ,Coagulation ,Immunology ,Chromatography, Gel ,Tyrosine ,Collagen ,Peptides ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
In addition to mediating the final common pathway of aggregation, the glycoprotein (GP) IIb/IIIa receptor participates in the activation of coagulation on the platelet surface. High-affinity conformation of GP IIb/IIIa in response to collagen-induced inside-out signalling seems to be mediated by GP VI(-FcRgamma) and reinforced by release of soluble mediators.We assessed the effects of the three currently available GP IIb/IIIa antagonists--abciximab, tirofiban and eptifibatide--on platelet aggregation induced by various procoagulant and GP VI-related agonists, i.e. collagen-related peptide (CRP), convulxin and collagen fibrils, in PPACK-anticoagulated platelet-rich plasma.At concentrations that equally inhibited 80% of ADP-induced maximal aggregation abciximab-inhibited GP VI-mediated platelet responses to CRP or convulxin significantly more than the low-molecular-weight antagonists (CRP: abciximab 75+/-18%, tirofiban 41+/-7% and eptifibatide 41+/-6%; convulxin: abciximab 90+/-6%, tirofiban 64+/-20%, eptifibatide 61+/-14%, p0.01 for all). In contrast, aggregation induced by collagen was equally abolished with all antagonists under the similar conditions. During CRP- or convulxin-triggered platelet activation, inhibition of fibrin polymerisation with GPRP potentiated the antiaggregatory effects of tirofiban and eptifibatide to reach that of abciximab. GPRP as such did not affect platelet aggregation.GP IIb/IIIa antagonists exhibit distinct inhibition profiles in platelet aggregation, depending on fibrin polymerization and calcium. Specifically, the ability of procoagulant platelet agonists to expose pre-activated and ligand-bound GP IIb/IIIa from the internal pool seems important.
- Published
- 2004
9. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial
- Author
-
Matti Porras, Jari Siironen, Riitta Lassila, Kristiina Poussa, Joona Varis, Juha Hernesniemi, Seppo Juvela, and Sorella Ilveskero
- Subjects
Male ,medicine.medical_specialty ,Subarachnoid hemorrhage ,medicine.drug_class ,Low molecular weight heparin ,Glasgow Outcome Scale ,Aneurysm, Ruptured ,law.invention ,Randomized controlled trial ,Double-Blind Method ,law ,medicine ,Humans ,cardiovascular diseases ,Prospective Studies ,Enoxaparin ,Prospective cohort study ,Nimodipine ,Intracerebral hemorrhage ,business.industry ,Anticoagulants ,Intracranial Aneurysm ,Middle Aged ,Subarachnoid Hemorrhage ,medicine.disease ,Combined Modality Therapy ,Surgery ,Treatment Outcome ,Anesthesia ,Female ,business ,Enoxaparin sodium ,medicine.drug - Abstract
Object. From the moment an intracranial aneurysm ruptures, cerebral blood flow is impaired, and this impairment mainly determines the outcome in patients who survive after the initial bleeding. The exact mechanism of impairment is unknown, but activation of coagulation and fibrinolysis correlate with clinical condition and outcome after aneurysmal subarachnoid hemorrhage (SAH). The purpose of this study was to determine whether enoxaparin, a low-molecular-weight heparin, which is a well-known anticoagulating agent, has any effect on the outcome of aneurysmal SAH postoperatively. Methods. In this randomized, double-blind, single-center clinical trial, 170 patients (85 per group) with aneurysmal SAH were randomly assigned to receive either enoxaparin (40 mg subcutaneously once daily) or a placebo, starting within 24 hours after occlusion of the aneurysm and continuing for 10 days. Analysis was done on an intention-to-treat basis. Outcome was assessed at 3 months on both the Glasgow Outcome and modified Rankin Scales. Patients were eligible for the study if surgery was performed within 48 hours post-SAH, and no intracerebral hemorrhage was larger than 20 mm in diameter on the first postoperative computerized tomography scan. At 3 months, there were no significant differences in outcome by treatment group. Of the 170 patients, 11 (6%) died, and only 95 (56%) had a good outcome. Principal causes of unfavorable outcome were poor initial condition, delayed cerebral ischemia, and surgical complications. There were four patients with additional intracranial bleeding in the group receiving enoxaparin. The bleeding was not necessarily associated with the treatment itself, nor did it require treatment, and there were no such patients in the placebo group. Conclusions. Enoxaparin seemed to have no effect on the outcome of aneurysmal SAH in patients who had already received routine nimodipine and who had received triple-H therapy when needed. Routine use of low-molecular-weight heparin should be avoided during the early postoperative period in patients with SAH, because this agent seems to increase intracranial bleeding complications slightly, with no beneficial effect on neurological outcome.
- Published
- 2004
10. A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines
- Author
-
Raija Silvennoinen, Muntasir Mamun Majumder, Dimitrios Tsallos, Hareth Nahi, Pekka Anttila, Anu Partanen, Sini Luoma, Anu Sikiö, Marita Nurmi, Ville Varmavuo, Marjaana Säily, Marja Sankelo, Esa Jantunen, Tarja-Terttu Pelliniemi, Sorella Ilveskero, Henrik Rode Eshoj, Lene Kongsgaard Nielsen, Samuli Eldfors, Aino-Maija Leppä, and Caroline Heckman
- Subjects
03 medical and health sciences ,Cancer Research ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Hematology ,030215 immunology
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.